Listed

DLH Holdings Corp.: Form 10-Q for the period ended Dec 31, 2024

Filed with the SEC on Feb 5, 2025 and accepted by EDGAR at Feb 5, 2025, 16:30 ET.

Share

Management's discussion and analysis

As filed, 31,364 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Forward-Looking and Cautionary Statements

You should read the following discussion in conjunction with the Consolidated Financial Statements and the notes to those statements included elsewhere in this Quarterly Report on Form 10-Q, as well as our Annual Report on Form 10-K for the year ended September 30, 2024, and in other reports we have subsequently filed with the SEC. This Quarterly Report on Form 10-Q contains certain statements that are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Certain statements contained in this Management’s Discussion and Analysis are forward-looking statements that involve risks and uncertainties. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward-looking statements that involve risks and uncertainties which could cause actual events or DLH’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements in this report include, among others, statements regarding benefits of acquisitions, estimates of future revenues, operating income, earnings, earnings per share, backlog, and cash flows. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements made in this report due to a variety of factors, including: the failure to achieve the anticipated benefits of any future acquisition (including anticipated future financial operating performance and results); the diversion of management’s attention from normal daily operations of the business and the challenges of managing larger and more widespread operations; the inability to retain employees and customers; contract awards in connection with re-competes for present business and/or competition for new business; our ability to manage our increased debt obligations; compliance with bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid and award protests, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; the impact of inflation and higher interest rates; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2024, as well as interim quarterly filings thereafter. The forward-looking statements contained herein are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and business. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements.

Overview and Background

DLH Holdings Corp. ("DLH") delivers improved health and readiness solutions for federal government customers through digital transformation, science research and development, and systems engineering and integration. We bring a unique combination of government sector experience, proven methodology, and unwavering commitment to solve the complex problems faced by civilian and military customers alike, doing so by leveraging multiple capabilities, including cyber technology, artificial intelligence, advanced analytics, cloud-based applications, and telehealth systems.

Competitive Advantages

We believe we are advantageously positioned within our markets through a number of features including, but not limited to:

  • highly credentialed workforce;
  • predominantly performing as the prime contractor;
  • strong past performance record across our government contracts; and
  • strong bipartisan support for our key contracts.

We have invested in leading credentials and capabilities that we expect will deliver value to our customers. These investments include development of secure Information Technology ("IT") platforms; sophisticated data analytic tools and techniques; and implementation process improvement and quality assurance programs and techniques. We are actively pursuing additional credentials that will support our customers' ever evolving missions.

Solutions and Services

We primarily focus on improved deployment and efficiency of large-scale health and defense initiatives for multiple agencies within the federal government, including the Department of Health and Human Services ("HHS"), the Department of Veterans Affairs ("VA"), Department of Defense ("DoD"), and many of their sub-agencies.

We deliver services primarily through prime contracts awarded by the federal government through competitive bidding processes. We have a diverse mix of contract vehicles with various agencies of the federal government, which supports our overall corporate growth strategy. Our revenue is distributed to time and materials contracts (54.4%), firm fixed price contracts (25.6%), and cost reimbursable contracts (20.0%).

We provide the following services and solutions, which are aligned with the long-term needs of our customers:

  • Digital Transformation and Cyber Security;
  • Science Research and Development; and
  • Systems Engineering and Integration

Digital Transformation and Cyber Security

We provide critical digital transformation and cyber security solutions across the federal civilian and cyber defense communities, leveraging advanced technology to modernize obsolete systems, protect sensitive information, manage large datasets, enhance operational efficiency and implement robotic process automation. Our suite of tools includes artificial intelligence and machine learning, cloud enablement, cybersecurity ecosystem, big data analytics, and modeling and simulation.

IT modernization and cyber security maturity are priority initiatives throughout our customer set. Our customers, including numerous institutes and centers within the National Institutes of Health ("NIH"), the Defense Health Agency ("DHA"), Telemedicine and Advanced Technology Research Center ("TATRC"), and US Navy, rely on our information technology support to enable their vital missions. We work with these customers to reduce risk and build resilience to cyber and physical threats to the federal government’s infrastructure, providing the full spectrum of cyber capabilities, cryptographic and true cyber engineering, Certified Information Security Officer ("CISO") / Information System Security Officer ("ISSO") support, risk management frameworks, Continuity of Operations ("COOP") / Disaster Recovery, and enterprise infrastructure and cloud governance focused on designing and implementing zero trust architecture.

Science Research and Development

We advance scientific knowledge and understanding through our extensive research portfolio and domain expertise. We primarily provide large-scale data analytics, testing and evaluation, clinical trials research services, and epidemiology studies to support multiple operating divisions within HHS, including NIH and the Center for Disease Control and Prevention ("CDC"), as well as the Military Health System.

Our employees support innovative, cutting-edge research on emerging trends, health informatics analyses, and application of best practices including mobile, social, and interactive media. We leverage evidence-based methods and web technology to drive health equity to our most vulnerable populations through public engagement. Projects often involve highly specialized expertise and transformative R&D support services. Our decades of experience designing, conducting, and analyzing studies for our diverse customer base, and our full-service clinical research solutions are designed for each customer’s specific research development program. Our employees provide expert knowledge and experience that supports our customers’ missions.

System Engineering and Integration

Our employees specialize in delivering engineering solutions that support our customers' evolving needs by rapidly deploying resources, solutions, and services. This includes specialized engineering expertise, encompassing areas of Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance, and Reconnaissance ("C5ISR"), modeling, simulation & training, performance based logistics, system modernization, technology-enabled health solutions and software engineering on behalf of the US Navy, HHS, VA, and other federal customers.

We utilize automation to accelerate infrastructure innovation and help customers define a lifecycle for automation assets, as well as set standards for version control, testing, and release processes that proved a robust foundation for their customers. DLH delivers IT operational resilience and efficiency in parallel with technology innovation integration, via hybrid and multi-cloud solutions, leveraging integrated services, process automation, advanced tool stacks, and mature quality processes. Our employees engineer, implement, and operate solutions that demonstrate measurable results to satisfy our customer’s management requirements, thus helping customers to confidently deploy secure platforms and technologies that reduce operational costs. We have invested in agile software development credentials for our technical staff, and have achieved Capability Maturity Model Integration ("CMMI") level 3. Our enterprise lifecycle logistics support services encompass military systems deployed worldwide, as well as scientific and IT systems and peripherals for Federal civilian agencies.

Major Customers

Our revenues are from agencies of the U.S. Federal government. A major customer is defined as a customer from whom we derive at least 10% of our revenues. The following table summarizes revenue by customer as follows (in thousands and percent):

Three Months Ended December 31, 2024 Revenue Percent of total revenue 2023 Revenue Percent of total revenue
Department of Health and Human Services $41,948 46.2% $44,297 45.3%
Department of Veterans Affairs 34,099 37.6% 34,680 35.4%
Department of Defense 13,355 14.7% 16,871 17.2%
Other customers with less than 10% share of total revenue 1,380 1.5% 2,002 2.1%
Total revenue $90,782 100.0% $97,850 100.0%

We remain dependent upon the continuation of our relationships with our major customers as a significant portion of our revenue is concentrated in each of them. Our results of operations, cash flows and financial condition would be materially adversely affected if we were unable to continue our relationship with any of these customers, if we were to lose any of our material current contracts, or if the amount of services we provide to them is materially reduced.

Major Contracts

We operate primarily through prime contracts awarded by the government through competitive bidding processes. We have a diverse mix of contract vehicles with various agencies of the U.S. government, which supports our overall corporate growth strategy. A major contract is defined as a contract or set of contracts from which we derive at least 10% of our revenues.

The revenue attributable to the VA was derived from separate task orders covering the Company's performance of pharmacy and logistics services at various regional locations, in support of the VA's Consolidated Mail Outpatient Pharmacy ("CMOP") program.

  • CMOP pharmacy and logistic services represent approximately $34.1 million and $34.7 million of revenues for the quarter ended December 31, 2024 and 2023, respectively.
  • For the quarter, we operated under the task orders issued at the close of fiscal 2024. Those task orders had varying durations up to four months. The task order for our Hines, Illinois location ended on January 31, 2025 as the site transitions to a new service-disabled veteran owned small business (“SDVOSB”) prime contractor. The task orders for the remaining six sites are expected to be extended to April 30, 2025. As discussed below, further extensions may be requested by the VA.

In connection with DLH’s continuing performance as the prime contractor during the VA's ongoing acquisition evaluation, the VA awarded us a sole-source Indefinite Quantity/Indefinite Delivery ("IDIQ") contract effective May 1, 2024. The IDIQ has a ceiling value of $200.0 million and a maximum period of performance through April 30, 2025, with the potential for orders placed within that period to extend performance beyond April 2025. The seven locations where we continue to provide services are under task orders awarded through this vehicle.

During the quarter ended June 30, 2024, the VA issued amendments to the requests for proposals for the seven remaining CMOP locations, which continue to give preference to an SDVOSB as a prime contractor. The amendments required a current or potentially new bidder to respond to the solicitations' changes with a compliant proposal. As with all proposal opportunities, DLH evaluated the revised CMOP requests for proposal for suitability of terms and conditions. As a result, we elected to not pursue certain opportunities at select locations.

Proposals were due for four of the seven locations during the quarter ended September 30, 2024. The remaining three locations have not yet had their proposal due dates assigned. While the acquisition and transition process is being conducted, DLH continues to operate as the prime contractor for all seven CMOP locations that it currently manages. DLH intends to provide additional updates to the progression of these solicitations as a part of its regular quarterly and annual filings.

Backlog

At December 31, 2024, our backlog was approximately $665.3 million of which $135.2 million was funded backlog. At September 30, 2024, our backlog was approximately $690.3 million, of which $155.1 million was funded backlog.

We define backlog as our estimate of remaining future revenue from existing signed contracts, assuming the exercise of all options relating to such contracts and including executed task orders issued under IDIQ contracts or if the contract is a single award IDIQ contract.

We define funded backlog as the portion of backlog for which funding is appropriated and allocated to the contract by the customer and authorized for payment by the customer, once specified work is completed. Funded backlog does not include the full contract value as Congress often appropriates funding for contracts on a yearly or quarterly basis.

Circumstances and events may cause changes in the amount of our backlog and funded backlog, including the execution of new contracts, extension of existing contracts, non-renewal or completion of current contracts, early termination, and adjustments to estimates. Changes in funded backlog may be affected by the funding cycles of the government. While no assurances can be given that existing contracts will result in earned revenue in any future period, or at all, our major customers have historically exercised their contractual renewal options.

Backlog value is quantified from management's judgment and assumptions about the volume of services based on past volume trends and current planning developed with customers.

Forward-Looking Business Trends

Our mission is to expand our position as a trusted provider of technology-powered health and readiness services and solutions to active duty personnel, veterans, and civilian populations and communities. These services and solutions are derived from three capabilities sets: Digital Transformation and Cybersecurity, Systems Engineering and Integration and Science Research and Development. Within these capabilities, our scientists and technology professionals provide solutions spanning robotic process automation, cloud migration and computing, enterprise IT systems management, modeling & simulation, data analytics and scientific research. We believe business development priorities in these areas will position the Company to expand within top national priority programs and funded areas.

Federal budget outlook for fiscal year 2025:

On December 20, the U.S. House and Senate passed a Continuing Resolution ("CR") to extend federal spending through March 14, 2025. Under this CR, Federal agencies will continue to operate at fiscal 2024 levels. When a CR expires, unless new appropriations bills have been passed by Congress and signed by the President, or a new CR is passed and signed into law, the government must cease operations, or shutdown, except in certain emergency situations or when the law authorizes continued activity. We are monitoring the impact the new Presidential Administration will have on government funding negotiations as their legislative and political priorities. We continuously review our operations in an attempt to identify programs potentially at risk from CRs so that we can consider appropriate contingency plans. Historically, our customers’ missions have received bipartisan support from the legislative and executive branches of the federal government. However, as the new administration and new Congress will seek to implement their budget priorities, and policies, we will continue to monitor the process for opportunities and impacts to our customers’ projects and budgets.

Potential impact of federal contractual set-aside laws and regulations:

The Federal government has an overall goal of 23% of prime contracts flowing through small businesses. As previously reported, various agencies within the federal government have policies that support small business goals, including the adoption of the “Rule of Two” by the VA, which provides that the agency shall award contracts by restricting competition for the contract to service-disabled or other veteran-owned businesses. To restrict competition pursuant to this rule, the contracting officer must reasonably expect that at least two of these businesses, which are capable of delivering the services, will submit offers and that the award can be made at a fair and reasonable price that offers best value to the U.S. When two qualifying small businesses cannot be identified, the VA may proceed to award contracts following a full and open bid process.

The Company believes that its past performance in this market and track record of success provide a competitive advantage. However, the effect of set-aside provisions may limit our ability to compete for prime contractor positions on programs that we recompete or that we have targeted for growth. In these cases, the Company may elect to join a team with an eligible contractor as prime for specific pursuits that align with our core markets and corporate growth strategy.

During the quarter ended December 31, 2024, we generated revenues of approximately $34.1 million from our set of contracts in support of the VA's CMOP program. As previously reported, the VA has been soliciting proposals for new contracts covering this work with a preference for a Service-Disabled Veteran Owned Small Business, or SDVOSB, to perform as the prime contractor. To date, the VA has awarded two locations to a new SDVOSB prime contractor. The remaining six locations continue to be operated by DLH as the prime contractor. Should awards for the locations for which we have submitted a proposal be offered to a partner of DLH, we expect to continue to perform a significant amount of those contracts' volume of business as a subcontractor.

Results of Operations

The following table summarizes results of operations for the three months ended December 31, 2024 and 2023 (in thousands except for per share amounts, and percentage of revenue):

Consolidated Statements of Operations: Three Months Ended December 31 2024 2023 Change
Revenue $90,782 100.0% $97,850 100.0% $(7,068)
Cost of operations:
Contract costs 72,382 79.7% 79,081 80.8% (6,699)
General and administrative costs 8,456 9.3% 7,697 7.9% 759
Depreciation and amortization 4,307 4.7% 4,253 4.3% 54
Total operating costs 85,145 93.8% 91,031 93.0% (5,886)
Income from operations 5,637 6.2% 6,819 7.0% (1,182)
Interest expense 4,133 4.6% 4,658 4.9% (525)
Income before provision for income tax 1,504 1.7% 2,161 2.2% (657)
Provision for income tax expense 389 0.4% 10 —% 379
Net income $1,115 1.2% $2,151 2.2% $(1,036)
Net income per share - basic $0.08 $0.15 $(0.07)
Net income per share - diluted $0.08 $0.15 $(0.07)

Revenue

Revenue decreased $7.1 million for the three months ended December 31, 2024 over 2023, primarily reflecting the conversion of certain contracts in our VA and DOD portfolios to small business contractors.

Cost of Operations

Contract costs primarily include the costs associated with providing services to our customers. These costs are generally comprised of direct labor and associated fringe benefit costs, subcontract cost, other direct costs, and the related management and infrastructure costs. Contract costs decreased $6.7 million for the three months ended December 31, 2024 over 2023; the decrease was primarily due to a decrease in revenue volume from low margin non-labor costs and a decrease in our overhead costs.

General and administrative costs are for those employees not directly providing services to our customers, to include but not limited to executive management, business development, accounting, and human resources. These costs increased $0.8 million for the three months ended December 31, 2024 as compared to 2023. As a percentage of revenue, general and administrative costs increased to 9.3% from 7.9%, with the increase being primarily due to an increase in business development expenses.

For the three months ended December 31, 2024, depreciation and amortization expense were approximately $0.2 million and $4.1 million, respectively, as compared to approximately $0.1 million and $4.1 million for the three months ended December 31, 2023, respectively.

Interest Expense, net

Interest expense, net, includes interest expense on the Company's term loan and amortization of deferred financing costs on debt obligations. Interest expense decreased $0.5 million for the three months ended December 31, 2024 over 2023, primarily due to the prepayment of debt and a decrease in the floating interest rate.

Provision for Income Tax Expense

Provision for income tax expense increased $379.0 thousand for the three months ended December 31, 2024 over 2023. The effective tax rate for the three months ended December 31, 2024 and 2023 was 25.9% and 0.4%, respectively. The tax provision from the prior year period was positively impacted by the exercise of non-qualifying stock options.

Non-GAAP Financial Measures

The Company uses Earnings Before Interest, Tax, Depreciation, and Amortization ("EBITDA") as a supplemental non-GAAP measure of our performance. DLH defines EBITDA as net income excluding (i) depreciation and amortization, (ii) interest expense, and (iii) provision for income tax expense.

On a non-GAAP basis, EBITDA for the three months ended December 31, 2024 and 2023 was approximately $9.9 million and $11.1 million, respectively. The decrease was primarily due to the decrease in revenue volume driven by conversion of certain VA and DoD contracts to small business contractors.

This non-GAAP measure of our performance is used by management to conduct and evaluate its business during its regular review of operating results for the periods presented. Management and our Board utilize this non-GAAP measure to make decisions about the use of our resources, analyze performance between periods, develop internal projections and measure management's performance. We believe that this non-GAAP measure is useful to investors in evaluating our ongoing operating and financial results and understanding how such results compare with our historical performance. By providing this non-GAAP measure as a supplement to GAAP information, we believe this enhances investors understanding of our business and results of operations. EBITDA is not a recognized measurement under accounting principles generally accepted in the United States, or GAAP, and when analyzing our performance investors should (i) evaluate adjustments in our reconciliation to the nearest GAAP financial measures and (ii) use non-GAAP measures in addition to, and not as an alternative to, measures of our operating results as defined under GAAP.

Reconciliation of GAAP net income to EBITDA, a non-GAAP measure (in thousands):

Three Months Ended December 31, 2024 2023 Change
Net income $1,115 $2,151 $(1,036)
(i) Depreciation and amortization 4,307 4,253 54
(ii) Interest expense, net 4,133 4,658 (525)
(iii) Provision for income tax expense 389 10 379
EBITDA $9,944 $11,072 $(1,128)

Liquidity and capital management

Cash was approximately $0.5 million and $0.3 million for the period ended December 31, 2024 and September 30, 2024, respectively.

Available borrowings under our revolving credit facility was approximately $11.8 million and $18.1 million for the period ended December 31, 2024 and September 30, 2024, respectively. The decrease is primarily due to increased borrowing under the revolving credit facility for the period ended December 31, 2024.

A summary of the change in cash is presented as follows (in thousands):

Three Months Ended December 31, 2024 2023 Change
Net cash (used in) provided by operating activities $(11,538) $5,071 $(16,609)
Net cash used in investing activities (552) (174) (378)
Net cash provided (used in) by financing activities 12,199 (4,981) 17,180
Net change in cash $109 $(84) $193

Cash flows used in and provided by operating activities totaled approximately $(11.5) million and $5.1 million for the three months ended December 31, 2024 and 2023, respectively. The decrease in cash from operations was principally due to an increase in accounts receivable due to a short-term decrease in collections.

Cash used in investing activities totaled $(0.6) million and $(0.2) million for the three months ended December 31, 2024 and 2023, respectively. The cash utilized was predominantly due capital expenditures in the three months ended December 31, 2024 and 2023, respectively.

Cash provided by and used in financing activities during the three months ended December 31, 2024 and 2023 were approximately $12.2 million and $(5.0) million, respectively. The cash provided by financing activities was principally to satisfy short-term working capital needs for the three months ended December 31, 2024.

Sources of cash

As of December 31, 2024, our immediate sources of liquidity include cash of approximately $0.5 million, accounts receivable, and access to our secured revolving line of credit facility. This credit facility provides us with access of up to $50.0 million, subject to certain conditions including eligible accounts receivable. As of December 31, 2024, we had unused borrowing capacity of $11.8 million, which is net of outstanding letters of credit. The Company's present operating liabilities are largely predictable and consist of vendor and payroll related obligations. We believe that our current investment and financing obligations are adequately covered by cash generated from profitable operations and that planned operating cash flow should be sufficient to support our operations for twelve months from the date of issuance of these consolidated financial statements.

Credit Facilities

A summary of our credit facilities for the period ended December 31, 2024 is as follows (in thousands):

Arrangement Loan Balance Interest* Maturity Date
Secured term loan (a) due December 8, 2027 $142,500 SOFR1 + 4.1% December 8, 2027
Secured revolving line of credit (b) due December 8, 2027 $24,459 SOFR1 + 4.1% December 8, 2027

1Secured Overnight Financing Rate ("SOFR") as of December 31, 2024 was 4.6%.

On January 31, 2023, we executed a floating-to-fixed interest rate swap with FNB which has a notional amount of $80.0 million at December 31, 2024, a fixed interest rate of 4.10% and a maturity date of January 31, 2026. As a result of entering these agreements, for the three months ended December 31, 2024, interest expense has been decreased by approximately $0.1 million.

(a) Represents the principal amounts payable on our term loan, which is secured by liens on substantially all of the assets of the Company. The principal of the term loan is payable in quarterly installments with the remaining balance due on December 8, 2027.

(b) As amended, the secured revolving line of credit has a ceiling of up to $50.0 million and a maturity date of December 8, 2027. The Company has accessed funds from the revolving credit facility during the quarter and has a balance outstanding at December 31, 2024 of $24.5 million.

The secured term loan and secured revolving line of credit are secured by liens on substantially all of the assets of the Company. The provisions of our credit facilities are fully described in Note 7. Credit Facilities to the consolidated financial statements.

Contractual Obligations

Contractual obligations as of December 31, 2024 are as follows (in thousands):

Ref Total Payments Due by Period Next 12 Months 2-3 Years 4-5 Years More than 5 Years
Debt obligations $166,959 $29,209 $137,750 $— $—
Facility operating leases (a) 19,314 2,814 6,693 5,927 3,880
Total contractual obligations $186,273 $32,023 $144,443 $5,927 $3,880

(a) The increase in facility operating lease obligations was due to an extension executed during the period to an existing lease.

Critical Accounting Policies and Estimates

Our critical accounting policies and estimates are disclosed in the Critical Accounting Policies and Estimates section in Part II, “Item 7. Management's Discussion of our Annual Report on Form 10-K for the year ended September 30, 2024. There have been no significant changes to the Company’s critical accounting policies as disclosed in our Annual Report on Form 10-K for the year ended September 30, 2024. For a detailed discussion on the application of accounting policies, refer to Note 2. Significant Accounting Policies.

Market risk

As filed, 970 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Except as described elsewhere in this report, the Company has not engaged in trading practices in securities or other financial instruments and therefore does not have any material exposure to interest rate risk, foreign currency exchange rate risk, commodity price risk or other similar risks, which might otherwise result from such practices. The Company has limited foreign operations and therefore is not materially subject to fluctuations in foreign exchange rates, commodity prices or other market rates or prices from market sensitive instruments. We have executed a set of floating-to-fixed interest rate swaps with a total notional amount of $80.0 million at December 31, 2024. The remaining balance of our debt is subject to floating interest rates.

We have determined that a 1.0% increase to SOFR would impact our interest expense by approximately $0.9 million per year. As of December 31, 2024, the interest rate on the floating interest rate debt was 8.7%.

Controls and procedures

As filed, 2,310 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Our CEO and President and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based on the evaluation of these controls and procedures, our disclosure controls and procedures were effective at the reasonable assurance level to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 (i) is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and (ii) that such information is accumulated and communicated to our management, including our CEO and President and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Our management, including our CEO and President and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. Our management, however, believes our disclosure controls and procedures are in fact effective to provide reasonable assurance that the objectives of the control system are met.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) identified in connection with the evaluation of our internal controls that occurred during the fiscal quarter ended December 31, 2024, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 1,364 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our operating results and financial condition have varied in the past and may in the future vary significantly depending on a number of factors. In addition to the other information set forth in this report, you should carefully consider the factors discussed in the “Risk Factors” section in our Annual Report on Form 10-K for the year ended September 30, 2024 and in our other reports filed with the SEC concerning the risks associated with our business, financial condition and results of operations. These factors, among others, could materially and adversely affect our business, results of operations, financial condition or liquidity and cause our actual results to differ materially from those contained in statements made in this report and presented elsewhere by management from time to time. The risks we have identified in our reports are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently believe are immaterial may also materially adversely affect our business, results of operations, financial condition or liquidity. See Item 1A, Risk Factors, in our Annual Report on Form 10-K for the fiscal year ended September 30, 2024. We believe that there have been no material changes from the risk factors described in our Annual Report on Form 10-K for the fiscal year ended September 30, 2024.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2024-10-01 to 2024-12-31$90.8mus-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
Operating income3 months2024-10-01 to 2024-12-31$5.6mus-gaap:OperatingIncomeLoss
Income tax3 months2024-10-01 to 2024-12-31$389.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2024-10-01 to 2024-12-31$1.1mus-gaap:ProfitLoss
Diluted EPS3 months2024-10-01 to 2024-12-31$0.08us-gaap:EarningsPerShareDiluted
Basic EPS3 months2024-10-01 to 2024-12-31$0.08us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2024-10-01 to 2024-12-3114,563,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2024-10-01 to 2024-12-31−$11.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2024-10-01 to 2024-12-31$552.0kus-gaap:PaymentsToAcquireProductiveAssets
Cash and equivalentsAt period end2024-12-31$451.0kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2024-12-31$67.6mus-gaap:AssetsCurrent
Total assetsAt period end2024-12-31$325.0mus-gaap:Assets
Current liabilitiesAt period end2024-12-31$64.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2024-12-31$213.6mus-gaap:Liabilities
Long-term debtAt period end2024-12-31$134.6mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2024-12-31$27.6mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2024-12-31$111.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000785557-25-000016. Last ingested by Listed: Oct 27, 2026, 17:13 ET. Listed shows no prices and gives no investment advice.